Literature DB >> 29223863

What can predict and prevent the long-term use of benzodiazepines?

Takeo Hata1, Tetsufumi Kanazawa2, Takeshi Hamada3, Masami Nishihara3, Ashley Ian Bush4, Hiroshi Yoneda5, Miki Nakajima6, Takahiro Katsumata3.   

Abstract

Although benzodiazepines (BZDs) are commonly prescribed for insomnia or anxiety, long-term use of BZDs causes serious adverse effects such as daytime drowsiness and cognitive decline. In the current study, we evaluated the predictors and preventers of long-term usage of BZDs from a retrospective survey by utilizing the 12-year prescription record of a university hospital. From the prescription data of 92,005 people, users of BZDs (n = 3,470, male = 39.2%, mean age = 60 ± 17.5) were analyzed. During this period, both the number of prescriptions (2722 in 2004 to 1019 in 2016) and the number of BZDs (1.73 in 2004 to 1.36 in 2016) gradually decreased, although more than half of the patients continued to take BZDs for over three years. High risk factors for long-term use of BZDs include elderly patients (>65 years old), high dosage (>5 mg diazepam per day), psychiatrist-prescribers, and users with polytherapy. Discontinuation is significantly found in users of hypnotic BZDs and alternative psychotropic medical drugs (including antipsychotics, serotonergic drugs, or newer types of sleep medicine). Future studies should focus on elucidating interventions that are more effective against long-term usage of BZDs.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Benzodiazepines (BZDs); Long-term use; Pharmacy; Psychiatry; Retrospective survey; Sleep medicine

Mesh:

Substances:

Year:  2017        PMID: 29223863     DOI: 10.1016/j.jpsychires.2017.11.012

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  7 in total

1.  Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.

Authors:  Shanna L Burke; Tianyan Hu; Christine E Spadola; Tan Li; Mitra Naseh; Aaron Burgess; Tamara Cadet
Journal:  Sleep Med       Date:  2018-09-20       Impact factor: 3.492

2.  Comparisons Between Successful Versus Unsuccessful Switches From Benzodiazepines or Zolpidem (Z-Drug) to Controlled-Release Melatonin in Patients With Major Depressive Disorder and Insomnia.

Authors:  Ji Hyun An; Mi Jin Park; Maurizio Fava; David Mischoulon; Hyewon Kim; Jihoon Jang; Jin Pyo Hong; Jun Sang Park; Hong Jin Jeon
Journal:  Front Psychiatry       Date:  2020-05-19       Impact factor: 4.157

3.  Prescribing Pattern of Hypnotic Medications in Patients Initiating Treatment at Japanese Hospitals: A Nationwide, Retrospective, Longitudinal, Observational Study Using a Claims Database.

Authors:  Ken Inada; Minori Enomoto; Kentaro Yamato; Kazuo Mishima
Journal:  Drugs Real World Outcomes       Date:  2021-03-13

4.  The Characteristics of Benzodiazepine Prescribing in the Republic of Srpska, Bosnia and Herzegovina.

Authors:  Žana M Maksimović; Mladen Stajić; Miloš P Stojiljković; Svjetlana Stoisavljević Šatara; Nataša Stojaković; Ranko Škrbić
Journal:  Medicina (Kaunas)       Date:  2022-07-22       Impact factor: 2.948

5.  Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland.

Authors:  Heidi Taipale; Hanna Särkilä; Antti Tanskanen; Terhi Kurko; Tero Taiminen; Jari Tiihonen; Reijo Sund; Annamari Tuulio-Henriksson; Leena Saastamoinen; Jarmo Hietala
Journal:  JAMA Netw Open       Date:  2020-10-01

6.  Risk of long-term benzodiazepine and Z-drug use following the first prescription among community-dwelling adults with anxiety/mood and sleep disorders: a retrospective cohort study.

Authors:  Jaden Brandt; Donica Janzen; Silvia Alessi-Severini; Alexander Singer; Dan Chateau; Murray Enns; Christine Leong
Journal:  BMJ Open       Date:  2021-11-01       Impact factor: 2.692

Review 7.  Benzodiazepine high-doses: The need for an accurate definition.

Authors:  Jean-Marc Cloos; Christopher Y S Lim Cow; Valéry Bocquet
Journal:  Int J Methods Psychiatr Res       Date:  2021-07-31       Impact factor: 4.035

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.